Clinical Trial Update: A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 study of talimogene laherparepvec (T-VEC) in stage IIIc and stage IV malignant melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Talimogene laherparepvec (T-VEC) (talimogene laherparepvec)

Snippet

Sponsor: BioVex Limited | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-18